Neurodegenerative disorders with prominent filamentous a-synuclein (a-syn) aggregates in CMS neurons or glia are known as ct-synucleinopathies or synuclienopathies, and those characterized by neuronal a-syn inclusions, or Lewy bodies (LBs) and neurites (LNs) D, include Parkinson's disease without dementia (PD), PD with dementia (PDD) and dementia with LBs (DLB). Most PD is sporadic, but mutations/duplications in the a-syn gene of rare kindreds cause autosomal dominant hereditary PD and PDD/DLB. Thus, filamentous a-syn inclusions are linked to the onset/progression of synucleinopathies, and this is re-enforced by studies in which we showed that transgenic (TG) mice engineered to express human a-syn develop neuronal and glial a-syn pathologies that recapitulate their human counterparts. We now propose to test hypotheses that a-syn which accumulates as insoluble aggregates cause cognitive impairments in PDD and DLB and these deficits are augmented by the presence of tau and/or p amyloid neuropathologies. To accomplish this, we will use brain samples obtained from Core C to compare the regional distribution of a-syn, tau and Ap neuropathology in clinically well defined PD, PDD/DLB and LB variant of Alzheimer's disease patients follwed in Core B and studied by Projects 1 and 2. Since existing a-syn TG mouse models we and others generated are inadequate to evaluate the contributions of these filamentous protein lesions to cognitive impairments, new TG mouse models with regulated overexpression of wild type (WT) or mutant a-syn in forebrain neurons will be developed to specifically address this issue. Finally, the role of regulated overexpression of tau tangles and Ap plaques in enhancing cognitive decline in the new a-syn TG mouse models will be evaluated, and comparisons of these TG mice with human disease samples from Core C will be performed in Aims 1-4 to establish verisimilitude of our models to human synucleinopathies. Taken together, our work will lead to more informative models of synucleinopathies and address important questions on mechanisms leading to a-syn pathologies and their contribution to brain degeneration in synucleinopathies.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Specialized Center (P50)
Project #
1P50NS053488-01A2
Application #
7246776
Study Section
Special Emphasis Panel (ZNS1-SRB-E (21))
Project Start
Project End
Budget Start
2007-06-15
Budget End
2008-05-31
Support Year
1
Fiscal Year
2007
Total Cost
$257,866
Indirect Cost
Name
University of Pennsylvania
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Shi, Min; Tang, Lu; Toledo, Jon B et al. (2018) Cerebrospinal fluid ?-synuclein contributes to the differential diagnosis of Alzheimer's disease. Alzheimers Dement 14:1052-1062
Tropea, Thomas F; Xie, Sharon X; Rick, Jacqueline et al. (2018) APOE, thought disorder, and SPARE-AD predict cognitive decline in established Parkinson's disease. Mov Disord 33:289-297
Portelius, Erik; Olsson, Bob; Höglund, Kina et al. (2018) Cerebrospinal fluid neurogranin concentration in neurodegeneration: relation to clinical phenotypes and neuropathology. Acta Neuropathol 136:363-376
Polinski, Nicole K; Volpicelli-Daley, Laura A; Sortwell, Caryl E et al. (2018) Best Practices for Generating and Using Alpha-Synuclein Pre-Formed Fibrils to Model Parkinson's Disease in Rodents. J Parkinsons Dis 8:303-322
Rey, Nolwen L; George, Sonia; Steiner, Jennifer A et al. (2018) Spread of aggregates after olfactory bulb injection of ?-synuclein fibrils is associated with early neuronal loss and is reduced long term. Acta Neuropathol 135:65-83
Lewczuk, Piotr; Riederer, Peter; O'Bryant, Sid E et al. (2018) Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. World J Biol Psychiatry 19:244-328
Simuni, Tanya; Caspell-Garcia, Chelsea; Coffey, Christopher S et al. (2018) Baseline prevalence and longitudinal evolution of non-motor symptoms in early Parkinson's disease: the PPMI cohort. J Neurol Neurosurg Psychiatry 89:78-88
Alcolea, Daniel; Irwin, David J; Illán-Gala, Ignacio et al. (2018) Elevated YKL-40 and low sAPP?:YKL-40 ratio in antemortem cerebrospinal fluid of patients with pathologically confirmed FTLD. J Neurol Neurosurg Psychiatry :
Luna, Esteban; Decker, Samantha C; Riddle, Dawn M et al. (2018) Differential ?-synuclein expression contributes to selective vulnerability of hippocampal neuron subpopulations to fibril-induced toxicity. Acta Neuropathol 135:855-875
Zee, Jarcy; Xie, Sharon X (2018) The Kaplan-Meier Method for Estimating and Comparing Proportions in a Randomized Controlled Trial with Dropouts. Biostat Epidemiol 2:23-33

Showing the most recent 10 out of 339 publications